FDA’s Clinical Trial Inclusion Policy Sold As Mild And Gentle
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Bob Temple says encouraging broader populations in clinical trials should not affect study size or enrichment designs.